Real-World check: is heart drug verquvo safe for korean patients?

NCT ID NCT06148935

Recruiting now Knowledge-focused Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study observes 1350 Korean adults with chronic heart failure who are prescribed Verquvo by their doctors. Researchers will track side effects and heart-related events over up to 12 months to see how safe and effective the drug is in everyday use. No experimental treatments are given—just routine care and data collection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Many Locations

    RECRUITING

    Multiple Locations, South Korea